Synonyms: AF710B
Compound class:
Synthetic organic
Comment: ANAVEX 3-71 is an oral, small molecule dual agonist of the σ1 (SIGMAR1) and M1 muscarinic acetylcholine receptors. Based on structure we matched ANAVEX 3-71 to AF710B, which appears to be the active S enantiomer of racemic AF710, in US20110281903A1 [3]. AF710B is described as both a M1 partial agonist and positive allosteric modulator in this patent and in peer reviewed articles [2,4]. AF710B was originally investigated for disease-modifying potential in Alzhermer's disease [1-2,4-6].
|
|
No information available. |
Summary of Clinical Use ![]() |
ANAVEX 3-71 is a clinical candidate for schizophrenia. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT06245213 | A Study of ANAVEX3-71 in Adults With Schizophrenia | Phase 2 Interventional | Anavex Life Sciences Corp. |